32.16  6.76 (26.61%)		10-03 16:00
Open: 26.7 High: 51.33 Volume: 647,399		Pre. Close: 25.4 Low: 26.4601 Market Cap: 1,412(M)

Short term
Mid term
Targets	6-month :	46.9	1-year :	59.95
Resists	First :	40.15	Second :	51.33
Pivot price	37.17
Supports	First :	22.07	Second :	18.37
MAs	MA(5) :	32.75	MA(20) :	39.1
	MA(100) :	33.67	MA(250) :	0
MACD	MACD :	-3.7	Signal :	-2.8
%K %D	K(14,3) :	20.9	D(3) :	18.7
RSI	RSI(14): 38.9
52-week	High :	55.65	Low :	5.32

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NNNN ] has closed above bottom band by 24.2%. Bollinger Bands are 36.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	51.4 - 51.69	51.69 - 51.95
Low:	26.06 - 26.26	26.26 - 26.44
Close:	31.81 - 32.16	32.16 - 32.48

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Thu, 20 Feb 2025
Fresh Biotech Player Enters Nasdaq: Will Anbio's $8M IPO Fuel Its Global Expansion? - Stock Titan

Thu, 20 Feb 2025
Anbio Biotechnology prices $8M IPO at $5 per share - MSN

Thu, 20 Feb 2025
Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq - Nasdaq

Wed, 19 Feb 2025
NNNN Stock Price and Chart — NASDAQ:NNNN - TradingView

Tue, 18 Feb 2025
Medical Tech Pioneer Anbio Sets $8M IPO Launch: Strategic Expansion Plans Revealed - Stock Titan

Thu, 02 Jan 2025
Anbio Biotechnology Pursues US IPO For IVD Products Launch (Pending:NNNN) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.8 (%)
Shares Short	164 (K)
Shares Short P.Month	154 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.4
Profit Margin	28.9 %
Operating Margin	-68.7 %
Return on Assets (ttm)	7.1 %
Return on Equity (ttm)	14.8 %
Qtrly Rev. Growth	-36.1 %
Gross Profit (p.s.)	0.13
Sales Per Share	0.18
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	2 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	643.2
PEG Ratio	0
Price to Book value	78.43
Price to Sales	172.34
Price to Cash Flow	678.6

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.